Entera Bio Ltd. 8-K

What Happened
Entera Bio Ltd. (ENTXW) announced an amended and restated collaboration and license agreement with OPKO Health, Inc. and OPKO Biologics Ltd. dated February 3, 2026 that expands the original agreement (from March 16, 2025) to include collaboration on a daily long‑acting PTH tablet (LA‑PTH) for hypoparathyroidism and other indications. Development costs for the LA‑PTH program will be shared equally between Entera Bio and OPKO. Separately, Gerald Ostrov notified the board of his resignation effective February 1, 2026, and the board appointed Steven D. Rubin (OPKO Executive VP – Administration) as a Class III director effective February 1, 2026; Mr. Rubin will serve as a member of the compensation committee and as Chairman of the audit committee. The A&R Collaboration Agreement is filed as Exhibit 10.1 and a press release was issued February 4, 2026.

Key Details

• A&R Collaboration Agreement effective February 3, 2026 expands scope to include preclinical and clinical development of a daily long‑acting PTH tablet (LA‑PTH).
• Development costs for the LA‑PTH program will be shared 50/50 between Entera Bio and OPKO.
• Director change: Gerald Ostrov resigned (notice Jan 29, 2026; effective Feb 1, 2026); Steven D. Rubin appointed Feb 1, 2026 and named audit committee chair and compensation committee member.
• Board determined Mr. Rubin is independent under SEC/Nasdaq rules and qualifies as an “audit committee financial expert.” Press release dated Feb 4, 2026 furnished as Exhibit 99.1.

Why It Matters

• The amended agreement formally adds a new development program (LA‑PTH) to Entera’s collaboration with OPKO, potentially expanding Entera’s clinical pipeline beyond the original oral dual agonist program.
• Equal cost‑sharing for LA‑PTH development means Entera and OPKO will split development expenses for that program, which affects how development risk and capital needs are allocated.
• The appointment of Steven Rubin (an OPKO executive with legal and board experience) to Entera’s board, and his role as audit committee chair, is a notable governance change that may affect oversight of financial reporting and the partnership with OPKO.